2.99
+0.18(+6.41%)
Currency In USD
Address
321 Summer Street
Boston, MA 02210
United States of America
Phone
857 330 4340
Website
Sector
Healthcare
Industry
Biotechnology
Employees
59
First IPO Date
July 24, 2020
| Name | Title | Pay | Year Born |
| Dr. Douglas A. Treco Ph.D. | Chief Executive Officer & Chairman | 591,875 | 1958 |
| Dr. Matthew Winton Ph.D. | Senior Vice President & Chief Operating Officer | 526,431 | 1978 |
| Mr. Sanjay S. Subramanian M.B.A., M.S. | Senior Vice President, Chief Financial Officer, Principal Accounting Officer & Corporate Secretary | 626,233 | 1977 |
| Mr. Axel Bolte M.B.A., M.Sc. | Co-Founder, Senior Advisor & Director | 1.16M | 1972 |
| Mr. Stefan Riley | Director of Investor Relations | 0 | N/A |
| Dr. Demetrios Braddock M.D., Ph.D. | Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer | 0 | N/A |
| Dr. Soojin Kim Ph.D. | Senior Vice President & Chief Technical Operations Officer | 0 | N/A |
| Dr. David Thompson M.A., M.S., Ph.D. | Senior Vice President, Chief Scientific Officer & Chief Development Officer | 0 | N/A |
| Ms. Gayle Gironda | Senior Vice President & Chief People Officer | 0 | N/A |
| Dr. Yves Sabbagh Ph.D. | Chairman of Scientific Advisory Board & Senior Vice President | 0 | N/A |
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.